Zynex (OTCMKTS:ZYXI) Given New $10.75 Price Target at B. Riley

Share on StockTwits

Zynex (OTCMKTS:ZYXI) had its price objective increased by B. Riley from $9.00 to $10.75 in a research note published on Friday morning, BenzingaRatingsTable reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for Zynex’s Q3 2019 earnings at $0.05 EPS, Q4 2019 earnings at $0.06 EPS, FY2019 earnings at $0.25 EPS and FY2020 earnings at $0.34 EPS.

Separately, Zacks Investment Research raised Zynex from a sell rating to a hold rating in a report on Thursday, June 27th.

Shares of OTCMKTS ZYXI opened at $8.75 on Friday. The firm has a market capitalization of $291.34 million, a PE ratio of 39.77 and a beta of 1.05. Zynex has a 12-month low of $2.40 and a 12-month high of $11.75. The company has a fifty day moving average of $8.98.

Zynex (OTCMKTS:ZYXI) last posted its earnings results on Wednesday, July 31st. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $9.84 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. Equities research analysts predict that Zynex will post 0.28 earnings per share for the current year.

In related news, CEO Thomas Sandgaard sold 50,000 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $8.88, for a total value of $444,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniel J. Moorhead sold 25,000 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $7.17, for a total value of $179,250.00. The disclosure for this sale can be found here. Insiders sold 188,750 shares of company stock worth $1,499,223 in the last three months.

Several hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of Zynex during the second quarter worth about $37,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Zynex during the first quarter worth about $118,000. WealthTrust Axiom LLC purchased a new position in shares of Zynex during the first quarter worth about $132,000. Finally, Sigma Planning Corp purchased a new position in shares of Zynex during the first quarter worth about $63,000. 0.05% of the stock is currently owned by institutional investors.

About Zynex

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Further Reading: What is a balanced fund?

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GAP  Updates FY 2019 Earnings Guidance
GAP Updates FY 2019 Earnings Guidance
salesforce.com  Updates Q3 2020 Earnings Guidance
salesforce.com Updates Q3 2020 Earnings Guidance
salesforce.com  Issues FY 2020 Earnings Guidance
salesforce.com Issues FY 2020 Earnings Guidance
Adtalem Global Education  Releases FY 2020 Earnings Guidance
Adtalem Global Education Releases FY 2020 Earnings Guidance
Dicks Sporting Goods  Issues FY20 Earnings Guidance
Dicks Sporting Goods Issues FY20 Earnings Guidance
Hormel Foods  Issues FY19 Earnings Guidance
Hormel Foods Issues FY19 Earnings Guidance


© 2006-2019 Ticker Report